The DGKZ antibody targets diacylglycerol kinase zeta (DGKζ), a member of the DGK enzyme family that regulates cellular signaling by converting diacylglycerol (DAG) into phosphatidic acid (PA). DGKζ, encoded by the *DGKZ* gene, is notable for its role in modulating lipid-mediated signaling pathways, particularly in immune cells, neurons, and cancer. It influences processes like T-cell receptor signaling, insulin response, and neuronal development by balancing DAG and PA levels, which act as secondary messengers. Dysregulation of DGKζ has been linked to immune disorders, cancer progression, and neurological conditions, making it a focus in disease research.
DGKZ antibodies are critical tools for studying the protein’s expression, localization, and function. They are used in techniques like Western blotting, immunofluorescence, and immunoprecipitation to investigate DGKζ’s involvement in cellular mechanisms. Researchers often validate these antibodies using knockout controls to ensure specificity, as DGK isoforms share structural similarities. Additionally, DGKZ exists in multiple splice variants, and antibody selection must account for isoform-specific epitopes. Commercial DGKZ antibodies are widely available, but performance can vary between clones, requiring careful optimization. Understanding DGKζ’s dual roles in signaling and disease continues to drive the development and application of these reagents in both basic and translational research.